In the sole double-blind, randomized controlled trial testing a GLP-1 agonist against a placebo for the treatment of BED [124], no significant differences emerged in remission of binge eating or BED. This evidence concerns the gene GCG and X-linked cone dysfunction syndrome with myopia.